Locally Advanced Pancreatic Cancer Market to Grow with a CAGR of 9.89% through 2028
Integration of artificial intelligence and big data
analytics are expected to drive the Global Locally Advanced Pancreatic Cancer Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “Locally
Advanced Pancreatic Cancer Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Locally
Advanced Pancreatic Cancer Market stood at USD 824.55 million in 2022 and is
anticipated to grow with a CAGR of 9.89% in the forecast period, 2024-2028.
Pancreatic
cancer is a formidable adversary in the realm of oncology, known for its
aggressive nature and limited treatment options. Among the various stages of
pancreatic cancer, locally advanced pancreatic cancer (LAPC) poses a particular
challenge due to its proximity to vital structures within the abdomen and the
absence of surgical options.
One of the
primary drivers behind the growth of the Global LAPC Market is the alarming
rise in the incidence of pancreatic cancer. According to the World Cancer
Research Fund, pancreatic cancer is the 12th most common cancer globally, and
it is estimated that there were nearly 495,773 new cases in 2020. The
increasing prevalence of risk factors such as smoking, obesity, and a family
history of pancreatic cancer contributes to this rise. As more individuals are
diagnosed with locally advanced pancreatic cancer, the demand for effective
treatment options escalates, propelling the market forward. Early and accurate
diagnosis is essential for improving the prognosis of LAPC patients. Recent
advancements in diagnostic technologies have significantly contributed to the
market's growth. High-resolution imaging techniques such as magnetic resonance
imaging (MRI) and computed tomography (CT) scans, along with endoscopic
ultrasound (EUS), have revolutionized the detection and staging of pancreatic
cancer. These technologies enable healthcare providers to diagnose LAPC at an
earlier stage, providing a window of opportunity for intervention and
treatment.
Personalized medicine has emerged as a promising
approach in cancer treatment, including LAPC. Biomarker research has led to the
identification of specific genetic mutations and molecular markers associated
with pancreatic cancer. This knowledge allows for tailored treatment plans that
target the unique characteristics of each patient's cancer. For example,
therapies targeting the BRCA mutation have shown promise in certain cases of
LAPC. This personalized approach not only improves treatment outcomes but also
reduces adverse effects, boosting patient quality of life.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Locally Advanced Pancreatic Cancer Market.”
The Global LAPC Market is witnessing a surge in
innovative treatment modalities. Traditional treatment options, such as
chemotherapy and radiation therapy, continue to play a vital role in managing
LAPC. However, newer approaches, including targeted therapies and
immunotherapies, are on the horizon. Targeted therapies like nab-paclitaxel
(Abraxane) and gemcitabine have shown efficacy in improving survival rates and
are becoming integral components of LAPC treatment regimens. Immunotherapies,
which harness the body's immune system to fight cancer cells, are also being
explored in clinical trials for LAPC.
The Global Locally Advanced Pancreatic Cancer Market
is segmented into Therapy, Route of administration, End-User, regional
distribution, and company.
Based on the Therapy, Chemotherapy emerged as the
dominant segment in the global market for Global Locally Advanced Pancreatic
Cancer Market in 2022. Firstly, Chemotherapy has historically been a primary
treatment modality for Locally Advanced Pancreatic Cancer (LAPC). It is widely
used to control the growth and spread of cancer cells, manage symptoms, and
improve the quality of life for LAPC patients. Secondly, chemotherapy regimens,
such as FOLFIRINOX and gemcitabine/nab-paclitaxel, have shown efficacy in
clinical trials and real-world settings, contributing to their widespread
adoption. These regimens have become standard treatment options for LAPC due to
their potential to prolong survival and enhance tumor response rates. Furthermore,
the aggressive nature of LAPC often necessitates systemic treatment approaches
like chemotherapy. LAPC typically involves tumors that have invaded nearby
structures and organs, making them less amenable to surgical resection. In such
cases, chemotherapy plays a crucial role in reducing tumor size and potentially
rendering the tumor operable.
Based on the Route Of Administration, the Injectables
emerged as the dominant player in the global market for Global Locally Advanced
Pancreatic Cancer Market in 2022. Chemotherapy drugs, which are a mainstay in
the treatment of LAPC, are typically administered through intravenous (IV)
infusion or subcutaneous injection. This route ensures direct delivery of the
chemotherapy agents into the bloodstream, allowing for rapid distribution
throughout the body, including to the tumor site. IV chemotherapy is highly
effective in targeting rapidly dividing cancer cells and is often used as the
first-line treatment for LAPC. Certain targeted therapies used in the treatment of
LAPC, such as monoclonal antibodies and kinase inhibitors, are also
administered via intravenous infusion. This method allows for controlled and consistent
dosing, ensuring that the medications reach their intended targets.
Immunotherapies, which harness the body's immune
system to fight cancer, are frequently delivered through intravenous infusion.
This route allows for the precise administration of immunotherapeutic agents,
facilitating immune cell activation and enhancing the body's ability to target
cancer cells.
Based on the End Users, the Hospitals and clinics emerged
as the dominant player in the global market for Global Locally Advanced Pancreatic
Cancer Market in 2022 Hospitals and clinics are equipped with specialized
medical teams, including oncologists, surgeons, radiologists, and other
healthcare professionals with expertise in managing complex conditions like
LAPC. These facilities often house comprehensive cancer centers that offer a
multidisciplinary approach to diagnosis, treatment, and ongoing care, ensuring
that patients receive the best possible care for their specific needs. The
diagnosis and staging of LAPC often require advanced imaging technologies like
magnetic resonance imaging (MRI), computed tomography (CT) scans, and
endoscopic ultrasound (EUS). Hospitals and clinics have ready access to these
diagnostic tools, allowing for accurate disease assessment and staging, which is
crucial for treatment planning.
North America emerged as the dominant player in the
global Locally Advanced Pancreatic Cancer Market in 2022, holding the largest market share.
North America boasts some of the world's most advanced and sophisticated healthcare
infrastructure, with state-of-the-art hospitals, research facilities, and
cancer treatment centers. This robust healthcare system enables the region to
provide cutting-edge diagnosis and treatment options for Locally Advanced
Pancreatic Cancer (LAPC) patients.
Major companies operating in Global Locally
Advanced Pancreatic Cancer Market are:
- Glaxosmithkline Plc
- Merck & Co.,
Inc.
- Bristol-Myers Squibb
Company
- Getwell
- Ipsen
Biopharmaceuticals, Inc.
- Novartis
Pharmaceuticals Corporation
- Pfizer Inc.
- Bayer HealthCare
Pharmaceuticals, Inc.
- Genentech USA, Inc.
- AstraZeneca Plc
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Locally Advanced Pancreatic Cancer Market is poised for substantial growth in
the coming years, driven by several key factors. Firstly, advancements in
treatment modalities, with immunotherapy and targeted therapies showing
promising results in clinical trials. Additionally, the integration of
artificial intelligence and big data analytics is expected to enhance early
detection and treatment planning, improving patient outcomes. Rising awareness
about pancreatic cancer risk factors and symptoms is likely to lead to earlier
diagnosis, increasing the pool of eligible patients for treatment. Furthermore,
collaborations between pharmaceutical companies, research institutions, and
healthcare providers are accelerating the development of innovative therapies
and expanding access to clinical trials.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Locally Advanced Pancreatic Cancer
Market - Global Industry Size, Share,
Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy (Chemotherapy,
Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery), By Route of
administration (Oral, Injectables, Others), By End-User (Hospitals &
Clinics, Ambulatory Care Centers, Others) By Region and Competition”, has evaluated
the future growth potential of Global Locally Advanced Pancreatic Cancer Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Locally Advanced Pancreatic Cancer Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com